NEW YORK (GenomeWeb) – Intrexon today priced a public offering of almost 4.9 million shares of its common stock aimed at raising $200 million in gross proceeds. 

The Germantown, Maryland-based synthetic biology firm is offering 4,878,049 shares of its stock at $41 per share. Proceeds from the offering will go toward general corporate purposes and strategic acquisitions or investments, it said. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.